Your session is about to expire
← Back to Search
ION251 for Multiple Myeloma
Study Summary
This trial is testing a new cancer drug to see what the highest dose is that patients can tolerate, and what the recommended dose should be for future trials.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Your body has a very low number of a type of white blood cell called neutrophils.Your total bilirubin levels are higher than 1.3 times the upper limit of normal.Your hemoglobin level is less than 8.0 grams per deciliter.Your blood pressure is very high and not under control.You have multiple myeloma and have not responded well to or cannot tolerate the standard treatments for this condition.You have a history of certain rare blood disorders or conditions.You have a condition that makes you bleed a lot or have ongoing bleeding.You should be able to perform daily activities without any assistance or with a little help.Your blood platelet count is less than 50,000 per cubic millimeter.Your kidney function, measured as eGFR, is less than 50 mL/min/1.73 m^2.Your urine has a high level of albumin compared to creatinine.You have multiple myeloma that can be measured.Your liver enzymes (ALT or AST) are more than twice the normal level.
- Group 1: ION251
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
For what cohort of individuals is this clinical trial recruiting participants?
"To conduct this clinical trial, 80 suitable patients must be found. The sponsor of the study, Ionis Pharmaceuticals Inc., will oversee proceedings from various locations like UCLA Rrmc in LA and Barbara Ann Karmanos Cancer Institute in Detroit."
Has ION251 received clearance from the FDA?
"The safety of ION251 is rated a 1 due to limited research indicating its efficacy, as this trial is classified as Phase 1."
How many centers are overseeing this experiment?
"Participation in this trial is open at 15 different medical institutions such as UCLA Rrmc in Los Angeles, Barbara Ann Karmanos Cancer Institute in Detroit, and The University of Alabama at Birmingham Comprehensive Cancer Center. There are many other locations to consider if you wish to join the study."
Are new participants being recruited for this research endeavor?
"Clinicaltrials.gov confirms that this medical research is in search of participants. The original posting was made on January 20th 2021, with the most recent update occurring on September 21st 2022."
Share this study with friends
Copy Link
Messenger